Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol Dosing in Hemodialysis Patients with Secondary Hyperparathyroidism
NCT00307840Phase 4Completed
- Sponsor
- Papageorgiou General Hospital
- Start
- Feb 2005
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised, double-blind trial of paricalcitol in secondary hyperparathyroidism (SHPT), sponsored by Papageorgiou General Hospital. Primary endpoint: Achievement of desired iPTH levels (150 - 300 pg/mL) at 10 weeks. Started Feb 2005; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00307840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307840.